Rain Therapeutics Inc. announced the appointment of Rain co-founder Robert Doebele, M.D., Ph.D. as president and chief scientific officer. As president, Dr. Doebele will play a critical role in shaping the company’s corporate strategy and operations and will continue to provide his precision oncology expertise to advance Rain’s clinical pipeline and lead the company’s research and development efforts as CSO. Dr. Doebele co-founded Rain Therapeutics with Mr. Vellanki in April 2017 and has served as executive vice president and CSO. Prior to joining Rain full time in October 2020, Dr. Doebele served as associate professor of medicine in the division of medical oncology at the University of Colorado School of Medicine, director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and as principal investigator for the University of Colorado Lung Cancer Specialized Program of Research Excellence. Dr. Doebele’s laboratory research on NTRK gene fusions launched the TRK inhibitor field and he helped drive the clinical strategy and development of TRK inhibitors from Loxo and Ignyta as two of the first agnostic cancer drugs. In addition, he serves as a senior editor of the American Association for Cancer Research journal, Clinical Cancer Research, and was elected to the American Society for Clinical Investigation in 2018. In addition to Dr. Doebele’s appointment, several members of the Rain leadership team have been elevated to new roles effective May 14, 2021, including Vijaya Tirunagaru, Ph.D. as senior vice president and head of research; Kolbot By, Ph.D. as senior vice president, technical operations; Lucio Tozzi as senior vice president, clinical operations; and Nelson Cabatuan as senior vice president, finance & administration. For more information about the Rain leadership team.